Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
t-cell crawled date : 2021 - 09 - 07 save search
Citius Pharmaceuticals Acquires Dr. Reddy's Laboratories' License for Late-Phase 3 Oncology Immunotherapy (E7777) for the Treatment of Cutaneous T-Cell Lymphoma and other Cancer Indications
Published: 2021-09-07 (Crawled : 12:15) - biospace.com/
RDY | $71.49 -0.92% 0.0% 130K
|
Health Technology
|
| O: 0.1%
H: 0.0%
C: -0.48%
CTXR | $0.772 5.15% 4.9% 670K
|
Health Technology
|
| O: 3.37%
H: 5.93%
C: -1.4%
treatment immunotherapy therapy cancer license phase 3 t-cell e7777
Adaptimmune Enters into a Strategic Collaboration with Genentech to Research, Develop, and Commercialize Cancer-targeted Allogeneic T-cell Therapies
Published: 2021-09-07 (Crawled : 12:00) - biospace.com/
ADAP | $1.12 10.89% 9.82% 1.1M
|
Health Technology
|
| O: 23.48%
H: 11.8%
C: 4.43%
collaboration cancer research t-cell commercialization therapy
Gainers vs Losers
| 78% | 22% |
Top 10 Gainers
MTTR | News M | $4.6 164.37% 62.17% 28M
|
AGBA | $2.94 135.2% 57.48% 66M
|
Finance
EDBL | News | $6.46 71.81% 41.8% 2M
|
MTC | $2.25 44.23% 30.67% 6M
|
Technology Services
OPRT | News | $3.175 41.11% 29.13% 12M
|
Finance
SHIM | $3.05 35.56% 26.23% 1.1M
|
HKIT | $1.345 31.86% 24.16% 390K
|
Technology Services
ABVC | $1.36 30.77% 23.53% 7.4M
|
Wholesale Trade
OST | $0.512 28.0% 21.88% 290K
|
POET | $1.59 27.2% 21.38% 4.2M
|
Manufacturing
Your saved searches
Save your searches and get alerts when important news are released.